In this Issue
Medical Editors’ Page
By Allen C. Ho, MD; and Robert L. Avery, MD
By Somnath Chakraborty, MD
What you need to know for the new year.
By Joy Woodke, COE, OCS, OCSR
Its role and what it means for fellows in training.
By Daniel Su, MD; with Guarav K. Shah, MD; and James F. Vander, MD
Trading five sclerotomies for three.
By Gurkan Erdoğan, MD; Beril Tulu Aygun, MD; and Alper Agca, MD
Examining the role of subthreshold laser in the era of anti-VEGF.
By Matteo Forlini, MD; and Purva Date, DNB, FVRS; with Justyna Jędrychowska-Jamborska, MD; Krzysztof Morawski, MD, PhD; and Bożena Romanowska-Dixon, MD, PhD
Consider your patients’ age and work status when establishing a treatment plan.
By Ragui Sedeek, MD
Among the options being examined for the treatment of patients with DR and DME, how might anti-integrin therapy fit into the mix?
By Pravin U. Dugel, MD
Complications due to diabetes present challenges during surgery, and recent innovations have addressed them.
By Alan J. Franklin, MD, PhD
These cases demonstrate mastery of important and novel vitreoretinal surgical techniques.
By Michael A. Klufas, MD
A different viewing platform in the OR requires some adjustment.
By S.K. Steven Houston III, MD
Could blood be your friend during complex macular hole surgery? In some cases, maybe.
By María H. Berrocal, MD; and Luis A. Acaba, BA
Some retina surgeons recommend postoperative regimens from an older era. It may be time for a change.
By Peter A. Karth, MD, MBA
Management and treatment options for retinoblastoma have changed radically in recent decades.
By David H. Abramson, MD; and Jasmine H. Francis, MD
Rajat N. Agrawal, MD, MS, the CEO and president of Retina Global, explains the nonprofit’s efforts in this interview.
By Ashvini K. Reddy, MD; with Rajat N. Agrawal, MD, MS
Research suggests that this branch of complementary medicine may hold promise.
By Deepinder K. Dhaliwal, MD, LAc; and Siwei Zhou, MD
IN THE BACK
Your Destination for the Latest Developments in #Retina in Print and Online